Journal of Nuclear Science, Engineering and Technology (JONSAT)
In cooperation with the Iranian Nuclear Society

Theoretical and experimental studies of 161Tb production as a new therapeutic radionuclide at Tehran Research Reactor

Document Type : Research Paper

Authors

Mehdi Sharifi
Hassan yousefnia
Ali Bahrami Samani
Amirreza Jalilian
Samaneh Zolghadri
Mohammad GhanadiMaragheh
Abstract
Because of the suitable decay characteristics of terbium-161 (161Tb), it is a promising radioisotope for development of new therapeutic complexes and also a good alternative to 177Lu. In this study, the production routes of 161Tb are evaluated by both theoretical and experimental methods. In the theoretical approach the chain decay equations are solved and the activity of the radionuclide and all of the other products are obtained by imposing constant values in the equations. The main route for the 161Tb production is the 160Gd(n,γ)161Gd (β-)161Tb reaction as an indirect production method. In this method, natural or enriched gadolinium can be used. For the 161Tb production, 1 mg of natural gadolinium is irradiated at the Tehran Research Reactor, using thermal neutron flux of 3×1013 cm-2 s-1 for 34 hours. The activity of each product is evaluated by means of gamma spectrometry. The results show that about 0.11 mCi of 161Tb is produced in this condition. Due to confirmation of the calculations with experiments, it can be concluded that production of about 100 mCi of 161Tb is possible by a long time irradiation of 10 mg of enriched 160Gd.

Keywords

Terbium-161
Gadolinium
Therapeutic radionuclide
Tehran Research Reactor
[1] H. Uusijärvi, P. Bernhardt, F. Rösch, H.R. Maecke, E. Forssell-Aronsson, Electron-and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production, Journal of Nuclear Medicine, 47(5) (2006) 807-814.
 
[2] S. Lehenberger, C. Barkhausen, S. Cohrs, E. Fischer, J. Grünberg, A. Hohn, U. Köster, R. Schibli, A. Türler, K. Zhernosekov, The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy, Nuclear medicine and biology, 38(6) (2011) 917-924.
 
[3] C. Müller, K. Zhernosekov, U. Köster, K. Johnston, H. Dorrer, A. Hohn, N.T. Van Der Walt, A. Türler, R. Schibli, A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α-and β−-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative, Journal of Nuclear Medicine, 53(12) (2012) 1951-1959.
 
[4] C. Müller, J. Reber, S. Haller, H. Dorrer, P. Bernhardt, K. Zhernosekov, A. Türler, R. Schibli, Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate, European journal of nuclear medicine and molecular imaging, (2013) 1-10.
 
[5] J. Grünberg, D. Lindenblatt, H. Dorrer, S. Cohrs, K. Zhernosekov, U. Köster, A. Türler, E. Fischer, R. Schibli, Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model, European Journal of Nuclear Medicine and Molecular Imaging, (2014) 1-9.
 
[6] IAEA-TECDOC, Quantifying uncertainty in nuclear analytical measurements, (2004).

Home